1-10 of 10
Jorma Isola
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CIP2A Is Associated with Human Breast Cancer Aggressivity

Christophe Côme, Anni Laine, Maïa Chanrion, Henrik Edgren, Elina Mattila, Xiaoling Liu, Jos Jonkers, Johanna Ivaska, Jorma Isola, Jean-Marie Darbon, Olli Kallioniemi, Simon Thézenas, Jukka Westermarck
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5092–5100.
https://doi.org/10.1158/1078-0432.CCR-08-3283
Published: 12 August 2009
View article titled, CIP2A Is Associated with Human Breast Cancer Aggressivity
Open the PDF for CIP2A Is Associated with Human Breast Cancer Aggressivity in another window
Includes: Supplementary data
Journal Articles

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Harri Sihto, Johan Lundin, Tiina Lehtimäki, Maarit Sarlomo-Rikala, Ralf Bützow, Kaija Holli, Liisa Sailas, Vesa Kataja, Mikael Lundin, Taina Turpeenniemi-Hujanen, Jorma Isola, Päivi Heikkilä, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (13): 4103–4110.
https://doi.org/10.1158/1078-0432.CCR-07-5003
Published: 01 July 2008
View article titled, Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening
Open the PDF for Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening in another window
Includes: Supplementary data
Journal Articles

Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma

Sofia K. Gruvberger-Saal, Pär-Ola Bendahl, Lao H. Saal, Mervi Laakso, Cecilia Hegardt, Patrik Edén, Carsten Peterson, Per Malmström, Jorma Isola, Åke Borg, Mårten Fernö
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 1987–1994.
https://doi.org/10.1158/1078-0432.CCR-06-1823
Published: 02 April 2007
View article titled, Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma
Open the PDF for Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma in another window
Includes: Supplementary data
Journal Articles

Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

Mervi Laakso, Minna Tanner, Jonas Nilsson, Tom Wiklund, Björn Erikstein, Pirkko Kellokumpu-Lehtinen, Per Malmström, Nils Wilking, Jonas Bergh, Jorma Isola
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4185–4191.
https://doi.org/10.1158/1078-0432.CCR-06-0353
Published: 20 July 2006
View article titled, Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer
Open the PDF for Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer in another window
Journal Articles

Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer

Nina Linder, Johan Lundin, Jorma Isola, Mikael Lundin, Kari O. Raivio, Heikki Joensuu
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (12): 4372–4381.
https://doi.org/10.1158/1078-0432.CCR-04-2280
Published: 15 June 2005
View article titled, Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer
Open the PDF for Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer in another window
Journal Articles

Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization

Jorma Isola, Minna Tanner, Amanda Forsyth, Timothy G. Cooke, Amanda D. Watters, John M. S. Bartlett
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4793–4798.
https://doi.org/10.1158/1078-0432.CCR-0428-03
Published: 21 July 2004
View article titled, Interlaboratory Comparison of <em>HER-2</em> Oncogene Amplification as Detected by Chromogenic and Fluorescence <em>in situ</em> Hybridization
Open the PDF for Interlaboratory Comparison of <em>HER-2</em> Oncogene Amplification as Detected by Chromogenic and Fluorescence <em>in situ</em> Hybridization in another window
Journal Articles

Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients

Teemu T. Junttila, Matti Laato, Tero Vahlberg, Karl-Ove Söderström, Tapio Visakorpi, Jorma Isola, Klaus Elenius
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5346–5357.
Published: 12 November 2003
View article titled, Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: <subtitle>Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients</subtitle>
Open the PDF for Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: <subtitle>Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients</subtitle> in another window
Journal Articles

Amplification of erbB2 and erbB2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0 Breast Cancer: A Nationwide Population-based Study

Heikki Joensuu, Jorma Isola, Mikael Lundin, Tiina Salminen, Kaija Holli, Vesa Kataja, Liisa Pylkkänen, Taina Turpeenniemi-Hujanen, Karl von Smitten, Johan Lundin
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 923–930.
Published: 01 March 2003
View article titled, Amplification of <em>erbB2</em> and erbB2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0 Breast Cancer: <subtitle>A Nationwide Population-based Study</subtitle>
Open the PDF for Amplification of <em>erbB2</em> and erbB2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0 Breast Cancer: <subtitle>A Nationwide Population-based Study</subtitle> in another window
Journal Articles

HER-2 Amplification and Topoisomerase IIα Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil

Angelo Di Leo, David Gancberg, Denis Larsimont, Minna Tanner, Tero Jarvinen, Ghizlane Rouas, Stella Dolci, Jean-Yves Leroy, Marianne Paesmans, Jorma Isola, Martine J. Piccart
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 1107–1116.
Published: 01 May 2002
View article titled, HER-2 Amplification and Topoisomerase IIα Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil
Open the PDF for HER-2 Amplification and Topoisomerase IIα Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil in another window
Journal Articles

Genetic Alterations in ERBB2-amplified Breast Carcinomas

Jorma Isola, Lisa Chu, Sandy DeVries, Kouji Matsumura, Karen Chew, Britt Marie Ljung, Frederic M. Waldman
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 4140–4145.
Published: 01 December 1999
View article titled, Genetic Alterations in <em>ERBB2</em>-amplified Breast Carcinomas
Open the PDF for Genetic Alterations in <em>ERBB2</em>-amplified Breast Carcinomas in another window